Key Highlights

  • 9.14% is the indicated pre-market decline for ChronoScale Holdings Corporation (NASDAQ:CHRN) on November 18, 2026, to USD 8.85 from a calculated prior close of USD 9.74, a calculated move of -USD 0.89 per share.
  • 41.5 million is the USD Revenue ChronoScale Holdings Corporation (NASDAQ:CHRN) reported for the quarter ended August 31, 2026, up 148% from USD 16.7 million a year earlier, driven by AI hardware resale arrangements.
  • 42.5 million is the USD total net loss, or USD 0.29 per share, reported by ChronoScale Holdings Corporation (NASDAQ:CHRN) for the quarter, including USD 16.1 million from discontinued operations, with adjusted EBITDA of USD 5.9 million.
  • 328.2 million is the USD aggregate of customer prepayments disclosed by ChronoScale Holdings Corporation (NASDAQ:CHRN), which targets USD 1 billion of annualized run-rate revenue by calendar third quarter 2027 and holds USD 15.2 million of cash.

What Moved ChronoScale Holdings Corporation (NASDAQ:CHRN) in Pre-Market Trading on November 18, 2026 (-USD 0.89, -9.14%)

The indicated pre-market price of ChronoScale Holdings Corporation (NASDAQ:CHRN) on November 18, 2026 is USD 8.85, a pre-market move of -9.14% ahead of the 9:30 a.m. ET open. On a calculated basis, the prior close from the November 17, 2026 regular session was USD 9.74 (USD 8.85 divided by 0.9086), and the calculated USD move is -USD 0.89 (price minus prior close). Using about 145.6 million shares outstanding at August 31, 2026, the calculated market Capitalization is approximately USD 1.29 billion.

The Rationale: No Identified Catalyst After Fiscal First Quarter Results for ChronoScale Holdings Corporation (NASDAQ:CHRN)

No catalyst for the pre-market move was identified in published coverage. As general context, recently combined AI infrastructure companies with high revenue growth and large losses can swing sharply on sector sentiment and profit-taking. The company released fiscal first quarter results on October 15, 2026. The Business combination was completed on May 5, 2026, and the Legacy Ekso Bionics business was sold on September 30, 2026. Management disclosed a 50 MW AI compute deal with Microsoft and partnerships with Nutanix and Baseten Labs. The chief executive officer, Cenly Chen, cited disciplined execution at scale.

Valuation, Liquidity and Risks for ChronoScale Holdings Corporation (NASDAQ:CHRN)

Net loss from continuing operations was USD 26.4 million, or USD 0.18 per share, and adjusted EBITDA fell to USD 5.9 million from USD 9.4 million. Annualizing the quarter, revenue of USD 41.5 million implies about USD 166 million, so the calculated market capitalization is roughly 7.8 times annualized revenue, and the USD 1 billion run-rate target is a calculated 6.0 times that pace. Cash of USD 15.2 million is small beside USD 328.2 million of prepayments, which raises delivery, execution and customer concentration risks, alongside dilution and resale-margin pressure.

Where Things Stand

ChronoScale Holdings Corporation (NASDAQ:CHRN) is indicated at USD 8.85 in pre-market trading on November 18, 2026, down 9.14% from a calculated prior close of USD 9.74. No specific catalyst was identified in published coverage. The most recent quarter, ended August 31, 2026, showed revenue of USD 41.5 million, a total net loss of USD 42.5 million and cash of USD 15.2 million, alongside USD 328.2 million of customer prepayments and a USD 1 billion run-rate target for calendar third quarter 2027. Execution on AI compute deliveries is the central variable. Indications can change at the 9:30 a.m. ET open, and this article is not Investment advice.